ATE426597T1 - Benzamidderivate und deren verwendung als glucokinaseaktivierende mittel - Google Patents

Benzamidderivate und deren verwendung als glucokinaseaktivierende mittel

Info

Publication number
ATE426597T1
ATE426597T1 AT05708360T AT05708360T ATE426597T1 AT E426597 T1 ATE426597 T1 AT E426597T1 AT 05708360 T AT05708360 T AT 05708360T AT 05708360 T AT05708360 T AT 05708360T AT E426597 T1 ATE426597 T1 AT E426597T1
Authority
AT
Austria
Prior art keywords
glucocinase
benzamide derivatives
activate agents
activate
agents
Prior art date
Application number
AT05708360T
Other languages
German (de)
English (en)
Inventor
Craig Johnstone
Darren Mckerrecher
Kurt Pike
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34890799&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE426597(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0403593A external-priority patent/GB0403593D0/en
Priority claimed from GB0413386A external-priority patent/GB0413386D0/en
Priority claimed from GB0423039A external-priority patent/GB0423039D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE426597T1 publication Critical patent/ATE426597T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
AT05708360T 2004-02-18 2005-02-15 Benzamidderivate und deren verwendung als glucokinaseaktivierende mittel ATE426597T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0403593A GB0403593D0 (en) 2004-02-18 2004-02-18 Compounds
GB0413386A GB0413386D0 (en) 2004-06-16 2004-06-16 Compounds
GB0423039A GB0423039D0 (en) 2004-10-16 2004-10-16 Compounds

Publications (1)

Publication Number Publication Date
ATE426597T1 true ATE426597T1 (de) 2009-04-15

Family

ID=34890799

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05708360T ATE426597T1 (de) 2004-02-18 2005-02-15 Benzamidderivate und deren verwendung als glucokinaseaktivierende mittel

Country Status (17)

Country Link
US (2) US20080280872A1 (enExample)
EP (2) EP1718624B1 (enExample)
JP (1) JP2007523142A (enExample)
KR (1) KR20070007103A (enExample)
AR (1) AR047678A1 (enExample)
AT (1) ATE426597T1 (enExample)
AU (1) AU2005214132B9 (enExample)
BR (1) BRPI0507746A (enExample)
CA (1) CA2554310A1 (enExample)
DE (1) DE602005013491D1 (enExample)
ES (1) ES2322709T3 (enExample)
IL (1) IL177216A0 (enExample)
NO (1) NO20063452L (enExample)
RU (1) RU2392275C2 (enExample)
TW (1) TW200602028A (enExample)
UY (1) UY28756A1 (enExample)
WO (1) WO2005080359A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
MXPA05008619A (es) 2003-02-13 2005-11-04 Banyu Pharma Co Ltd Derivados novedosos de 2-piridincarboxamida.
EP1600442B1 (en) * 2003-02-26 2018-01-17 Msd K.K. Heteroarylcarbamoylbenzene derivative
EP1718624B1 (en) * 2004-02-18 2009-03-25 AstraZeneca AB Benzamide derivatives and their use as glucokinase activating agents
TW200600086A (en) * 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
CA2581619A1 (en) * 2004-10-16 2006-04-20 Astrazeneca Ab Process for making phenoxy benzamide compounds
GB0423043D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
GB0423042D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Chemical process
GB0423044D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
TW200714597A (en) * 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
NZ564608A (en) * 2005-07-09 2009-09-25 Astrazeneca Ab Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
AU2006299091A1 (en) 2005-09-29 2007-04-12 Sanofi-Aventis Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
US20070197532A1 (en) * 2005-11-18 2007-08-23 Cao Sheldon X Glucokinase activators
TW200738621A (en) * 2005-11-28 2007-10-16 Astrazeneca Ab Chemical process
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
US7910747B2 (en) 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
CA2657566A1 (en) 2006-07-24 2008-01-31 F. Hoffmann-La Roche Ag Pyrazoles as glucokinase activators
SA07280576B1 (ar) * 2006-10-26 2011-06-22 استرازينيكا ايه بي مركبات بنزويل أمينو سيكليل غير متجانسة بأعتبارها عوامل منشطة للجلوكوكيناز
JP2010513445A (ja) * 2006-12-21 2010-04-30 アストラゼネカ アクチボラグ Ｇｌｋアクチベーターとして有用な新規結晶性化合物
JP2010534722A (ja) 2007-07-27 2010-11-11 ブリストル−マイヤーズ スクイブ カンパニー 新規グルコキナーゼ活性化薬およびその使用方法
AU2008310115B2 (en) 2007-10-09 2013-06-27 Merck Patent Gmbh N- ( pyrazole- 3 -yl) -benzamide derivatives as glucokinase activators
BRPI0908124A2 (pt) * 2008-02-06 2015-08-04 Daiichi Sankyo Co Ltd Composto, ativador de glucoquinase, composição farmacêutica, uso de um composto ou sal farmacologicamente aceitavél do mesmo, e, métodos de ativação da glucoquinase, e para tratar e/ou prevenir uma doença
WO2009106209A1 (en) * 2008-02-27 2009-09-03 Merck Patent Gmbh Carboxamide-heteroaryl derivatives for the treatment of diabetes
US7741327B2 (en) 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
US8258134B2 (en) 2008-04-16 2012-09-04 Hoffmann-La Roche Inc. Pyridazinone glucokinase activators
JP2011529955A (ja) 2008-08-04 2011-12-15 アストラゼネカ アクチボラグ 治療薬４１４
WO2010082601A1 (ja) * 2009-01-16 2010-07-22 第一三共株式会社 新規２，５－二置換ピロール誘導体
GB0902434D0 (en) * 2009-02-13 2009-04-01 Astrazeneca Ab Chemical process
GB0902406D0 (en) * 2009-02-13 2009-04-01 Astrazeneca Ab Crystalline polymorphic form
WO2010116176A1 (en) * 2009-04-09 2010-10-14 Astrazeneca Ab Pyrazolo [4, 5-e] pyrimidine derivative and its use to treat diabetes and obesity
WO2010116177A1 (en) 2009-04-09 2010-10-14 Astrazeneca Ab A pyrazolo [4,5-e] pyrimidine derivative and its use to treat diabetes and obesity
JPWO2010128595A1 (ja) * 2009-05-07 2012-11-01 富士フイルムＲｉファーマ株式会社 放射性ヨウ素標識イミダゾピリジン誘導体の製造法
EP2445908A1 (en) 2009-06-22 2012-05-02 Cadila Healthcare Limited Disubstituted benzamide derivatives as glucokinase (gk) activators
MX2012001228A (es) 2009-07-31 2012-04-20 Cadila Healthcare Ltd Derivados de benzamida sustituidos como activadores de glucocinasa (gk).
KR20120120204A (ko) * 2009-12-11 2012-11-01 아스텔라스세이야쿠 가부시키가이샤 벤즈아미드 화합물
US8222416B2 (en) 2009-12-14 2012-07-17 Hoffmann-La Roche Inc. Azaindole glucokinase activators
WO2011122458A1 (ja) * 2010-03-29 2011-10-06 第一三共株式会社 含窒素芳香環化合物

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2750393A (en) * 1954-12-01 1956-06-12 Sterling Drug Inc Iodinated 5-henzamidotetrazoles and preparation thereof
US2967194A (en) * 1958-05-15 1961-01-03 Pennsalt Chemicals Corp 4-trifluoromethylsalicylamides
GB1400540A (en) * 1972-12-06 1975-07-16 Smith Kline French Lab Salicylamides and compositions thereof
US4009174A (en) * 1972-12-08 1977-02-22 The Boots Company Limited Esters of substituted nicotinic acids
GB1437800A (en) * 1973-08-08 1976-06-03 Phavic Sprl Derivatives of 2-benzamido-5-nitro-thiazoles
GB1561350A (en) * 1976-11-05 1980-02-20 May & Baker Ltd Benzamide derivatives
FR2344284A1 (fr) * 1976-03-17 1977-10-14 Cerm Cent Europ Rech Mauvernay Nouveaux composes tricycliques a cycle furannique et leur application comme antidepresseurs
US4474792A (en) * 1979-06-18 1984-10-02 Riker Laboratories, Inc. N-Tetrazolyl benzamides and anti-allergic use thereof
FR2493848B2 (fr) * 1980-11-07 1986-05-16 Delalande Sa Nouveaux derives des nor-tropane et granatane, leur procede de preparation et leur application en therapeutique
JPS59139357A (ja) * 1983-01-28 1984-08-10 Torii Yakuhin Kk アミジン誘導体
CA1327358C (en) * 1987-11-17 1994-03-01 Morio Fujiu Fluoro cytidine derivatives
US5466715A (en) * 1991-12-31 1995-11-14 Sterling Winthrop Inc. 3,4-disubstituted phenols-immunomodulating agents
US5258407A (en) * 1991-12-31 1993-11-02 Sterling Winthrop Inc. 3,4-disubstituted phenols-immunomodulating agents
US5273986A (en) * 1992-07-02 1993-12-28 Hoffmann-La Roche Inc. Cycloalkylthiazoles
US5661153A (en) * 1994-07-19 1997-08-26 Japan Energy Corporation 1-arylpyrimidine derivatives and pharmaceutical use thereof
US5510478A (en) * 1994-11-30 1996-04-23 American Home Products Corporation 2-arylamidothiazole derivatives with CNS activity
US5672750A (en) * 1994-12-16 1997-09-30 Eastman Chemical Company Preparation of aromatic amides from carbon monoxide, an amine and an aromatic chloride
US5849735A (en) * 1995-01-17 1998-12-15 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5712270A (en) * 1995-11-06 1998-01-27 American Home Products Corporation 2-arylamidothiazole derivatives with CNS activity
TW429241B (en) 1996-09-26 2001-04-11 Sumitomo Pharma Nitrone derivatives
AUPO395396A0 (en) * 1996-12-02 1997-01-02 Fujisawa Pharmaceutical Co., Ltd. Benzamide derivatives
FR2757852B1 (fr) * 1996-12-31 1999-02-19 Cird Galderma Composes stilbeniques a groupement adamantyl, compositions les contenant et utilisations
DE69826286T2 (de) * 1997-06-27 2005-11-24 Fujisawa Pharmaceutical Co., Ltd. Derivate mit einem aromatischen ring
BR9810456A (pt) * 1997-06-27 2001-09-25 Fujisawa Pharmaceutical Co Composto de sulfonamida, método para sua obtenção e seu uso farmacêutico
US6613942B1 (en) * 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6200995B1 (en) * 1998-01-29 2001-03-13 Tularik Inc. PPAR-γ modulators
DE19816780A1 (de) * 1998-04-16 1999-10-21 Bayer Ag Substituierte 2-Oxo-alkansäure-[2-(indol-3-yl)-ethyl]amide
GB9811969D0 (en) * 1998-06-03 1998-07-29 Celltech Therapeutics Ltd Chemical compounds
US6197798B1 (en) * 1998-07-21 2001-03-06 Novartis Ag Amino-benzocycloalkane derivatives
US6320050B1 (en) * 1999-03-29 2001-11-20 Hoffmann-La Roche Inc. Heteroaromatic glucokinase activators
US6610846B1 (en) * 1999-03-29 2003-08-26 Hoffman-La Roche Inc. Heteroaromatic glucokinase activators
BR0009486B1 (pt) 1999-03-29 2011-03-09 composto que compreende uma amida, composição farmacêutica que compreende esse composto, seu uso e processo para a preparação do mesmo.
RU2242469C2 (ru) * 1999-03-29 2004-12-20 Ф.Хоффманн-Ля Рош Аг Активаторы глюкокиназы
AU1917201A (en) * 1999-11-18 2001-05-30 Centaur Pharmaceuticals, Inc. Amide therapeutics and methods for treating inflammatory bowel disease
US6353111B1 (en) 1999-12-15 2002-03-05 Hoffmann-La Roche Inc. Trans olefinic glucokinase activators
AU2001245353A1 (en) * 2000-02-29 2001-09-12 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
US6534651B2 (en) * 2000-04-06 2003-03-18 Inotek Pharmaceuticals Corp. 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof
US6388071B2 (en) * 2000-05-03 2002-05-14 Hoffmann-La Roche Inc. Alkynyl phenyl heteroaromatic glucokinase activators
US7504417B2 (en) * 2000-11-22 2009-03-17 Astellas Pharma Inc. Substituted benzene derivatives or salts thereof
ES2256340T3 (es) * 2000-12-06 2006-07-16 F. Hoffmann-La Roche Ag Activadores heteroaromaticos fusionados de la glucoquinasa.
CA2432713C (en) * 2000-12-22 2009-10-27 Ishihara Sangyo Kaisha, Ltd. Aniline derivatives or salts thereof and cytokine production inhibitors containing the same
SE0102300D0 (sv) * 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
PL368129A1 (en) * 2001-08-09 2005-03-21 Ono Pharmaceutical Co, Ltd. Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
SE0102764D0 (sv) * 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
DE10161765A1 (de) * 2001-12-15 2003-07-03 Bayer Cropscience Gmbh Substituierte Phenylderivate
IL162620A0 (en) 2001-12-21 2005-11-20 Novo Nordisk As Amide derivatives as gk activators
AU2003221140B9 (en) * 2002-03-26 2009-07-30 Banyu Pharmaceutical Co., Ltd. Novel aminobenzamide derivative
AU2003232204B8 (en) 2002-04-26 2009-07-30 F. Hoffmann-La Roche Ag Substituted phenylacetamides and their use as glucokinase activators
KR101116627B1 (ko) 2002-06-27 2012-10-09 노보 노르디스크 에이/에스 치료제로서 아릴 카르보닐 유도체
JPWO2004007472A1 (ja) * 2002-07-10 2005-11-17 小野薬品工業株式会社 Ｃｃｒ４アンタゴニストおよびその医薬用途
GB0226931D0 (en) * 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
GB0226930D0 (en) * 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
EP1600442B1 (en) * 2003-02-26 2018-01-17 Msd K.K. Heteroarylcarbamoylbenzene derivative
GB0325402D0 (en) * 2003-10-31 2003-12-03 Astrazeneca Ab Compounds
US20050267182A1 (en) * 2003-11-13 2005-12-01 Ambit Biosciences Corporation Urea derivatives as FLT-3 modulators
GB0327760D0 (en) * 2003-11-29 2003-12-31 Astrazeneca Ab Compounds
GB0327761D0 (en) * 2003-11-29 2003-12-31 Astrazeneca Ab Compounds
GB0328178D0 (en) * 2003-12-05 2004-01-07 Astrazeneca Ab Compounds
KR20070007104A (ko) * 2004-02-18 2007-01-12 아스트라제네카 아베 화합물
EP1718624B1 (en) * 2004-02-18 2009-03-25 AstraZeneca AB Benzamide derivatives and their use as glucokinase activating agents
TW200600086A (en) * 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
PE20060598A1 (es) * 2004-09-13 2006-08-21 Ono Pharmaceutical Co Derivado heterociclo conteniendo nitrogeno como antagonista de quimiocina ccr5
GB0423043D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
GB0423044D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
CA2581619A1 (en) * 2004-10-16 2006-04-20 Astrazeneca Ab Process for making phenoxy benzamide compounds
TW200714597A (en) * 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
NZ564608A (en) * 2005-07-09 2009-09-25 Astrazeneca Ab Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
US20080234273A1 (en) * 2005-07-09 2008-09-25 Mckerrecher Darren Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes
US20090105263A1 (en) * 2005-09-16 2009-04-23 Peter William Rodney Caulkett Heterobicyclic compounds as glucokinase activators
TW200738621A (en) * 2005-11-28 2007-10-16 Astrazeneca Ab Chemical process
TW200825063A (en) * 2006-10-23 2008-06-16 Astrazeneca Ab Chemical compounds
SA07280576B1 (ar) * 2006-10-26 2011-06-22 استرازينيكا ايه بي مركبات بنزويل أمينو سيكليل غير متجانسة بأعتبارها عوامل منشطة للجلوكوكيناز
JP2010513445A (ja) * 2006-12-21 2010-04-30 アストラゼネカ アクチボラグ Ｇｌｋアクチベーターとして有用な新規結晶性化合物

Also Published As

Publication number Publication date
TW200602028A (en) 2006-01-16
EP1718624A1 (en) 2006-11-08
WO2005080359A1 (en) 2005-09-01
CA2554310A1 (en) 2005-09-01
AU2005214132B9 (en) 2009-06-25
JP2007523142A (ja) 2007-08-16
AU2005214132A1 (en) 2005-09-01
RU2006130684A (ru) 2008-03-27
UY28756A1 (es) 2005-09-30
KR20070007103A (ko) 2007-01-12
US20110034432A1 (en) 2011-02-10
EP1718624B1 (en) 2009-03-25
RU2392275C2 (ru) 2010-06-20
IL177216A0 (en) 2006-12-10
BRPI0507746A (pt) 2007-07-10
DE602005013491D1 (de) 2009-05-07
NO20063452L (no) 2006-10-31
ES2322709T3 (es) 2009-06-25
AR047678A1 (es) 2006-02-01
HK1096092A1 (en) 2007-05-25
EP2048137A1 (en) 2009-04-15
AU2005214132B2 (en) 2009-05-07
US20080280872A1 (en) 2008-11-13

Similar Documents

Publication Publication Date Title
ATE426597T1 (de) Benzamidderivate und deren verwendung als glucokinaseaktivierende mittel
DE602005004144D1 (de) Octahydropyrroloä3,4-cüpyrrolderivate und deren verwendung als antivirale mitteln
ATE543825T1 (de) Spiro-oxindolverbindungen und ihre verwendungen als therapeutische mittel
ATE378338T1 (de) Pyrrolopyridinderivate und deren verwendung als crth2-antagonisten
DE602004021904D1 (de) Gyraseinhibitoren und deren verwendungen
DE60321043D1 (de) Biphenylderivate und deren verwendung als fungizide
DE60308998D1 (de) N-aryl-2-oxazolidinon-5-carbonsäureamide und deren derivate und deren verwendung als antibakterielle mittel
ATE502925T1 (de) 6-alkyl- oder alkenyl-4-aminopicolinate und deren verwendung als herbizide
ATE472546T1 (de) 5-heteroarylthiazole und deren verwendung als pi3k-inhibitoren
DE602005001123D1 (de) Wässrige Emulsion und deren Verwendung
EP1746902A4 (en) MULTI-LECTIN AFFINITY CHROMATOGRAPHY AND USES THEREOF
ATE472549T1 (de) Octahydropyrroloä3,4-cüpyrrolderivate und ihre verwendung als antivirale mittel
EP1469860A4 (en) ANTICANCER COMBINATION AND USE THEREOF
DE502005007106D1 (de) Substituierte phenylaminothiazole und ihre verwendung
ATE511507T1 (de) Piperidinylcarbonylpyrrolidine und deren verwendung als melanocortinagonisten
EP1955844A4 (en) COMPOSITE SHEET AND USE THEREOF
DE602004028700D1 (de) Kosmetische Zusammensetzungen und deren Verwendung
ATE482957T1 (de) Arylessigsäure- und esterderivate und deren verwendung als entzündungshemmende mittel
DE602004008668D1 (de) Benzoxazinderivate und deren verwendungen
DE602006018166D1 (de) Polyrotaxanhaltige lösung und verwendung davon
DE602005009988D1 (de) Härtbare Zusammensetzung und deren Verwendung
ATE396185T1 (de) Substituierte 4-alkyl- und 4- alkanoylpiperidinderivate und deren verwendung als neurokininantagonisten
DE602005022060D1 (de) Diaminoalkohole und deren verwendung als renininhibitoren
ATE517098T1 (de) Acylaminothiazolderivate und deren verwendung als beta-amyloid-inhibitoren
DE60311277D1 (de) Benzotriazabicyclische derivate und deren verwendung als beta-lactamaseinhibitoren und antibakterielle mittel

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties